Subscribe to RSS
DOI: 10.1055/s-0031-1275528
Candida Prophylaxis and Therapy in the ICU
Publication History
Publication Date:
19 April 2011 (online)
ABSTRACT
The incidence of invasive candidiasis in critically ill patients has increased over the past decade and is associated with considerable morbidity and mortality. Candida is identified in up to 17% of ICU patients, with candidemia occurring in ∼1%. Candida albicans continues to account for approximately half of the invasive candidiasis cases, with non-albicans Candida species, such Candida glabrata, increasing in frequency. Diagnosis of invasive candidiasis is commonly based on blood culture results; however, the sensitivity of blood culture to identify Candida is low. Because early, appropriate therapy has been associated with improved outcomes, antifungal therapy is being implemented in critically ill patients with risk factors for candidemia (prophylaxis). Systemic antifungal therapy is also being utilized in patients at increased risk for invasive candidiasis based on surrogate markers of infection such as colonization (preemptive therapy), or in patients with unresolving sepsis despite appropriate management (empirical therapy). Recent guidelines on the use of antifungal therapy have better identified patients who can be treated with azole derivatives and those who may benefit from echinocandins or polyenes. However, prospective trials are still needed to better identify appropriate therapy for patients at risk for, or with, confirmed invasive Candida infections.
KEYWORDS
Candida - ICU - colonization - outcomes - echinocandins
REFERENCES
- 1 Wisplinghoff H, Bischoff T, Tallent S M, Seifert H, Wenzel R P, Edmond M B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004; 39 (3) 309-317
- 2 Horn D L, Fishman J A, Steinbach W J et al.. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis. 2007; 59 (4) 407-414
- 3 Richardson M D. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother. 2005; 56 (Suppl 1) i5-i11
- 4 Lipsett P A. Surgical critical care: fungal infections in surgical patients. Crit Care Med. 2006; 34 (9, Suppl) S215-S224
- 5 Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003; 3 (11) 685-702
- 6 Kullberg B J, Oude Lashof A M. Epidemiology of opportunistic invasive mycoses. Eur J Med Res. 2002; 7 (5) 183-191
- 7 Garbino J, Kolarova L, Rohner P, Lew D, Pichna P, Pittet D. Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine (Baltimore). 2002; 81 (6) 425-433
- 8 Pfaller M A, Diekema D J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007; 20 (1) 133-163
- 9 Tortorano A M, Peman J, Bernhardt H ECMM Working Group on Candidaemia et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis. 2004; 23 (4) 317-322
- 10 Arendrup M C, Fuursted K, Gahrn-Hansen B et al.. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect. 2008; 14 (5) 487-494
- 11 Arendrup M C, Fuursted K, Gahrn-Hansen B et al.. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol. 2005; 43 (9) 4434-4440
- 12 Poikonen E, Lyytikäinen O, Anttila V J, Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis. 2003; 9 (8) 985-990
- 13 Chen S, Slavin M, Nguyen Q Australian Candidemia Study et al. Active surveillance for candidemia, Australia. Emerg Infect Dis. 2006; 12 (10) 1508-1516
- 14 Hsueh P R, Teng L J, Yang P C, Ho S W, Luh K T. Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole. Microb Drug Resist. 2002; 8 (4) 311-319
- 15 Cao B, Wang H, Wu L, Sun W J, Li F, Liu Y M. Epidemiological study of invasive nosocomial candidiasis in 2 teaching hospitals in Beijing [in Chinese]. Zhonghua Yi Xue Za Zhi. 2008; 88 (28) 1970-1973
- 16 Almirante B, Rodríguez D, Park B J Barcelona Candidemia Project Study Group et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol. 2005; 43 (4) 1829-1835
- 17 Gudlaugsson O, Gillespie S, Lee K et al.. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003; 37 (9) 1172-1177
- 18 Morgan J, Meltzer M I, Plikaytis B D et al.. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol. 2005; 26 (6) 540-547
- 19 Zaoutis T E, Argon J, Chu J, Berlin J A, Walsh T J, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005; 41 (9) 1232-1239
- 20 Falagas M E, Apostolou K E, Pappas V D. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis. 2006; 25 (7) 419-425
- 21 Leleu G, Aegerter P, Guidet B. Collège des Utilisateurs de Base de Données en Réanimation . Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care. 2002; 17 (3) 168-175
- 22 Rentz A M, Halpern M T, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis. 1998; 27 (4) 781-788
- 23 Pelz R K, Lipsett P A, Swoboda S M et al.. Candida infections: outcome and attributable ICU costs in critically ill patients. J Intensive Care Med. 2000; 15 255-261
- 24 Wilson L S, Reyes C M, Stolpman M, Speckman J, Allen K, Beney J. The direct cost and incidence of systemic fungal infections. Value Health. 2002; 5 (1) 26-34
- 25 Wey S B, Mori M, Pfaller M A, Woolson R F, Wenzel R P. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med. 1988; 148 (12) 2642-2645
- 26 Olaechea P M, Palomar M, León-Gil C EPCAN Study Group et al. Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis. 2004; 23 (4) 323-330
- 27 Moran C, Grussemeyer C A, Spalding J R, Benjamin Jr D K, Reed S D. Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections. Am J Infect Control. 2010; 38 (1) 78-80
- 28 Hassan I, Powell G, Sidhu M, Hart W M, Denning D W. Excess mortality, length of stay and cost attributable to candidaemia. J Infect. 2009; 59 (5) 360-365
- 29 Hajjeh R A, Sofair A N, Harrison L H et al.. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol. 2004; 42 (4) 1519-1527
- 30 Yap H Y, Kwok K M, Gomersall C D et al.. Epidemiology and outcome of Candida bloodstream infection in an intensive care unit in Hong Kong. Hong Kong Med J. 2009; 15 (4) 255-261
- 31 Voss A, le Noble J L, Verduyn Lunel F M, Foudraine N A, Meis J F. Candidemia in intensive care unit patients: risk factors for mortality. Infection. 1997; 25 (1) 8-11
- 32 Nolla-Salas J, Sitges-Serra A, León-Gil C Study Group of Fungal Infection in the ICU et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Intensive Care Med. 1997; 23 (1) 23-30
- 33 Kett D H, Azoulay E, Echeverria P M, Vincent J L, Investigators E I. Candida bloodstream infections in the intensive care units: analysis of the Extended Prevalence of Infection in an Intensive Care Unit Study. Crit Care Med. 2011; 39 665-670
- 34 Aliyu S H, Enoch D A, Abubakar I I et al.. Candidaemia in a large teaching hospital: a clinical audit. QJM. 2006; 99 (10) 655-663
- 35 Bassetti M, Righi E, Costa A et al.. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006; 6 21
- 36 Kibbler C C, Seaton S, Barnes R A et al.. Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect. 2003; 54 (1) 18-24
- 37 Comert F, Kulah C, Aktas E, Eroglu O, Ozlu N. Identification of Candida species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3-year period. Mycoses. 2007; 50 (1) 52-57
- 38 Pfaller M A, Messer S A, Hollis R J et al.. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol. 2009; 47 (10) 3185-3190
- 39 Leroy O, Gangneux J P, Montravers P AmarCand Study Group et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med. 2009; 37 (5) 1612-1618
- 40 Laverdiere M, Labbé A C, Restieri C et al.. Susceptibility patterns of Candida species recovered from Canadian intensive care units. J Crit Care. 2007; 22 (3) 245-250
- 41 Marriott D JE, Playford E G, Chen S Australian Candidaemia Study et al. Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit Care. 2009; 13 (4) R115
- 42 Yin Q Q, Zhang Y T, Fang Q. Study on the morbidity and pathogens of patients with candidemia at the intensive care unit [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2008; 29 (5) 464-468
- 43 Pfaller M A, Boyken L, Hollis R J et al.. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. [Erratum in J Clin Microbiol 2008 Sep;46(9):3184–3185] J Clin Microbiol. 2008; 46 (1) 150-156
- 44 Colombo A L, Perfect J, DiNubile M et al.. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis. 2003; 22 (8) 470-474
- 45 Pappas P G, Rex J H, Lee J NIAID Mycoses Study Group et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003; 37 (5) 634-643
- 46 Bedini A, Venturelli C, Mussini C et al.. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. Clin Microbiol Infect. 2006; 12 (1) 75-80
- 47 Davis S L, Vazquez J A, McKinnon P S. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients. Ann Pharmacother. 2007; 41 (4) 568-573
- 48 Cohen Y, Karoubi P, Adrie C et al.. Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients. Crit Care Med. 2010; 38 (3) 826-830
- 49 Vincent J-L, Rello J, Marshall J EPIC II Group of Investigators et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009; 302 (21) 2323-2329
- 50 Choi H K, Jeong S J, Lee H S et al.. Bloodstream infections by Candida glabrata and Candida krusei: a single-center experience. Korean J Intern Med. 2009; 24 (3) 263-269
- 51 Hadley S, Lee W W, Ruthazer R, Nasraway Jr S A. Candidemia as a cause of septic shock and multiple organ failure in nonimmunocompromised patients. Crit Care Med. 2002; 30 (8) 1808-1814
- 52 Garrouste-Orgeas M, Timsit J F, Tafflet M OUTCOMEREA Study Group et al. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: a reappraisal. Clin Infect Dis. 2006; 42 (8) 1118-1126
- 53 Morrell M, Fraser V J, Kollef M H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005; 49 (9) 3640-3645
- 54 Garey K W, Rege M, Pai M P et al.. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006; 43 (1) 25-31
- 55 Puzniak L, Teutsch S, Powderly W, Polish L. Has the epidemiology of nosocomial candidemia changed?. Infect Control Hosp Epidemiol. 2004; 25 (8) 628-633
- 56 Guery B P, Arendrup M C, Auzinger G et al.. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients, I: Epidemiology and diagnosis. Intensive Care Med. 2009; 35 (1) 55-62
- 57 Vincent J L, Anaissie E, Bruining H et al.. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med. 1998; 24 (3) 206-216
- 58 Rex J H, Sobel J D. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis. 2001; 32 (8) 1191-1200
- 59 Blumberg H M, Jarvis W R, Soucie J M National Epidemiology of Mycoses Survey(NEMIS) Study Group et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis. 2001; 33 (2) 177-186
- 60 Sobel J D, Rex J H. Invasive candidiasis: turning risk into a practical prevention policy?. Clin Infect Dis. 2001; 33 (2) 187-190
- 61 Agvald-Ohman C, Klingspor L, Hjelmqvist H, Edlund C. Invasive candidiasis in long-term patients at a multidisciplinary intensive care unit: Candida colonization index, risk factors, treatment and outcome. Scand J Infect Dis. 2008; 40 (2) 145-153
- 62 León C, Ruiz-Santana S, Saavedra P EPCAN Study Group et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006; 34 (3) 730-737
- 63 León C, Ruiz-Santana S, Saavedra P Cava Study Group et al. Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009; 37 (5) 1624-1633
- 64 Dupont H, Paugam-Burtz C, Muller-Serieys C et al.. Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients. Arch Surg. 2002; 137 (12) 1341-1346 discussion 1347
- 65 Pelz R K, Lipsett P A, Swoboda S M, Diener-West M, Hammond J M, Hendrix C W. The diagnostic value of fungal surveillance cultures in critically ill patients. Surg Infect (Larchmt). 2000; 1 (4) 273-281
- 66 Michalopoulos A S, Geroulanos S, Mentzelopoulos S D. Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients. Chest. 2003; 124 (6) 2244-2255
- 67 Ostrosky-Zeichner L, Pappas P G, Shoham S et al.. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses. 2011; 54 (1) 46-51
- 68 Pittet D, Monod M, Suter P M, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994; 220 (6) 751-758
- 69 Pelz R K, Hendrix C W, Swoboda S M et al.. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg. 2001; 233 (4) 542-548
- 70 Ostrosky-Zeichner L, Pappas P G. Invasive candidiasis in the intensive care unit. Crit Care Med. 2006; 34 (3) 857-863
- 71 Azoulay E, Timsit J F, Tafflet M Outcomerea Study Group et al. Candida colonization of the respiratory tract and subsequent Pseudomonas ventilator-associated pneumonia. Chest. 2006; 129 (1) 110-117
- 72 Delisle M S, Williamson D R, Perreault M M, Albert M, Jiang X, Heyland D K. The clinical significance of Candida colonization of respiratory tract secretions in critically ill patients. J Crit Care. 2008; 23 (1) 11-17
- 73 Canadian Critical Care Trials Group . A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med. 2006; 355 (25) 2619-2630
- 74 Petri M G, König J, Moecke H P et al.. Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Med. 1997; 23 (3) 317-325
- 75 Charles P E, Dalle F, Aube H et al.. Candida spp. colonization significance in critically ill medical patients: a prospective study. Intensive Care Med. 2005; 31 (3) 393-400
- 76 Piarroux R, Grenouillet F, Balvay P et al.. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med. 2004; 32 (12) 2443-2449
- 77 Fricker-Hidalgo H, Lebeau B, Pelloux H, Grillot R. Use of the BACTEC 9240 System with Mycosis-IC/F blood culture bottles for detection of fungemia. J Clin Microbiol. 2004; 42 (4) 1855-1856, author reply 1855–1856
- 78 Gherna M, Merz W G. Identification of Candida albicans and Candida glabrata within 1.5 hours directly from positive blood culture bottles with a shortened peptide nucleic acid fluorescence in situ hybridization protocol. J Clin Microbiol. 2009; 47 (1) 247-248
- 79 Shepard J R, Addison R M, Alexander B D et al.. Multicenter evaluation of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization method for simultaneous dual-color identification of C. albicans and C. glabrata directly from blood culture bottles. J Clin Microbiol. 2008; 46 (1) 50-55
- 80 Ostrosky-Zeichner L, Alexander B D, Kett D H et al.. Multicenter clinical evaluation of the (1—> 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005; 41 (5) 654-659
- 81 Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1—> 3)-beta-D-glucan assay for the diagnosis of invasive fungal infections—a study based on autopsy cases from 6 years. Clin Infect Dis. 2008; 46 (12) 1864-1870
- 82 Odabasi Z, Mattiuzzi G, Estey E et al.. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004; 39 (2) 199-205
- 83 Fukazawa Y. Antigenic structure of Candida albicans: immunochemical basis of the serologic specificity of the mannans in yeasts. Immunol Ser. 1989; 47 37-62
- 84 Sendid B, Tabouret M, Poirot J L, Mathieu D, Fruit J, Poulain D. New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis. J Clin Microbiol. 1999; 37 (5) 1510-1517
- 85 Moragues M D, Ortiz N, Iruretagoyena J R et al.. Evaluation of a new commercial test (Candida albicans IFA IgG) for the serodiagnosis of invasive candidiasis [in Spanish]. Enferm Infecc Microbiol Clin. 2004; 22 (2) 83-88
- 86 Berzaghi R, Colombo A L, Machado A M, de Camargo Z P. New approach for diagnosis of candidemia based on detection of a 65-kilodalton antigen. Clin Vaccine Immunol. 2009; 16 (11) 1538-1545
- 87 Ahmad S, Khan Z, Mustafa A S, Khan Z U. Seminested PCR for diagnosis of candidemia: comparison with culture, antigen detection, and biochemical methods for species identification. J Clin Microbiol. 2002; 40 (7) 2483-2489
- 88 McMullan R, Metwally L, Coyle P V et al.. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis. 2008; 46 (6) 890-896
- 89 Schuster M G, Edwards Jr J E, Sobel J D et al.. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med. 2008; 149 (2) 83-90
- 90 Lam S W, Eschenauer G A, Carver P L. Evolving role of early antifungals in the adult intensive care unit. Crit Care Med. 2009; 37 (5) 1580-1593
- 91 Ostrosky-Zeichner L, Sable C, Sobel J et al.. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis. 2007; 26 (4) 271-276
- 92 Faiz S, Neale B, Rios E et al.. Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit. Eur J Clin Microbiol Infect Dis. 2009; 28 (6) 689-692
- 93 Garbino J, Lew D P, Romand J A, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med. 2002; 28 (12) 1708-1717
- 94 Garey K W, Neuhauser M M, Bearden D T et al.. Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses. 2006; 49 (3) 226-231
- 95 Shorr A F, Chung K, Jackson W L, Waterman P E, Kollef M H. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med. 2005; 33 (9) 1928-1935 quiz 1936
- 96 Playford E G, Webster A C, Sorrell T C, Craig J C. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev. 2006; (1) CD004920
- 97 Eggimann P, Francioli P, Bille J et al.. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med. 1999; 27 (6) 1066-1072
- 98 Magill S S, Swoboda S M, Shields C E et al.. The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial. Ann Surg. 2009; 249 (4) 657-665
- 99 Bassetti M, Ansaldi F, Nicolini L et al.. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother. 2009; 64 (3) 625-629
- 100 Rocco T R, Reinert S E, Simms H H. Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch Surg. 2000; 135 (2) 160-165
- 101 Pappas P G, Kauffman C A, Andes D Infectious Diseases Society of America et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48 (5) 503-535
- 102 Hadley S, Huckabee C, Pappas P G et al.. Outcomes of antifungal prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis. 2009; 11 (1) 40-48
- 103 Benedetti E, Gruessner A C, Troppmann C et al.. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J Am Coll Surg. 1996; 183 (4) 307-316
- 104 Guaraldi G, Cocchi S, Codeluppi M et al.. Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients. Transplantation. 2005; 80 (12) 1742-1748
- 105 Parkins M D, Sabuda D M, Elsayed S, Laupland K B. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother. 2007; 60 (3) 613-618
- 106 Shan Y S, Sy E D, Wang S T, Lee J C, Lin P W. Early presumptive therapy with fluconazole for occult Candida infection after gastrointestinal surgery. World J Surg. 2006; 30 (1) 119-126
- 107 Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo S K. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother. 2010; 54 (1) 184-190
- 108 Rex J H, Bennett J E, Sugar A M Candidemia Study Group and the National Institute et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med. 1994; 331 (20) 1325-1330
- 109 Phillips P, Shafran S, Garber G Canadian Candidemia Study Group et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis. 1997; 16 (5) 337-345
- 110 Mora-Duarte J, Betts R, Rotstein C Caspofungin Invasive Candidiasis Study Group et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002; 347 (25) 2020-2029
- 111 DiNubile M J, Lupinacci R J, Strohmaier K M, Sable C A, Kartsonis N A. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. J Crit Care. 2007; 22 (3) 237-244
- 112 Betts R F, Nucci M, Talwar D Caspofungin High-Dose Study Group et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis. 2009; 48 (12) 1676-1684
- 113 Pappas P G, Rotstein C M, Betts R F et al.. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007; 45 (7) 883-893
- 114 Reboli A C, Rotstein C, Pappas P G Anidulafungin Study Group et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007; 356 (24) 2472-2482
- 115 Ostrosky-Zeichner L, Oude Lashof A M, Kullberg B J, Rex J H. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis. 2003; 22 (11) 651-655
- 116 Kullberg B J, Sobel J D, Ruhnke M et al.. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005; 366 (9495) 1435-1442
- 117 Rex J H, Pappas P G, Karchmer A W National Institute of Allergy and Infectious Diseases Mycoses Study Group et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003; 36 (10) 1221-1228
- 118 Pachl J, Svoboda P, Jacobs F Mycograb Invasive Candidiasis Study Group et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis. 2006; 42 (10) 1404-1413
- 119 Karwa R, Wargo K A. Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009; 43 (11) 1818-1823
- 120 Kuse E-R, Chetchotisakd P, da Cunha C A Micafungin Invasive Candidiasis Working Group et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007; 369 (9572) 1519-1527
- 121 Rex J H, Bennett J E, Sugar A M NIAID Mycoses Study Group and the Candidemia Study Group et al. Intravascular catheter exchange and duration of candidemia. Clin Infect Dis. 1995; 21 (4) 994-996
- 122 Horn D L, Ostrosky-Zeichner L, Morris M I et al.. Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. Eur J Clin Microbiol Infect Dis. 2010; 29 (2) 223-229
- 123 Nucci M, Anaissie E, Betts R F et al.. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis. 2010; 51 (3) 295-303
Élie AzoulayM.D. Ph.D.
Hôpital Saint-Louis, Service de Reanimation
1 Avenue Claude Vellefaux, 75010 Paris, France
Email: elie.azoulay@sls.aphp.fr